Brasada Capital Management LP Acquires Shares of 61,699 Boston Scientific Corporation $BSX

Brasada Capital Management LP acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, Holdings Channel reports. The firm acquired 61,699 shares of the medical equipment provider’s stock, valued at approximately $2,633,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Coastal Bridge Advisors LLC bought a new position in Boston Scientific in the second quarter worth about $1,023,000. Public Employees Retirement System of Ohio bought a new stake in Boston Scientific during the 2nd quarter valued at approximately $24,391,000. MASTERINVEST Kapitalanlage GmbH purchased a new position in shares of Boston Scientific during the 2nd quarter worth approximately $2,822,000. Proficio Capital Partners LLC purchased a new position in shares of Boston Scientific during the 2nd quarter worth approximately $434,000. Finally, Pure Financial Advisors LLC bought a new position in shares of Boston Scientific in the 2nd quarter worth approximately $223,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Director Susan E. Morano reportedly purchased additional Boston Scientific shares, signaling confidence from an insider while the stock is near its recent lows. Top Boston Scientific Insider Makes Bold New Share Grab
• Neutral Sentiment: The company’s latest quarterly results had been stronger than expected, with adjusted EPS and revenue exceeding consensus estimates and revenue rising year over year. However, that earnings momentum may provide limited near-term support while the cyber incident remains unresolved.
• Negative Sentiment: Boston Scientific said the cyberattack disrupted information systems used to process customer orders and ship products worldwide. The company is working to restore access, but the timing of a full recovery remains unclear, raising the risk of shipment delays, lost sales, remediation costs and weaker near-term results. Boston Scientific hit by cyberattack, global operations affected
• Negative Sentiment: The cybersecurity disruption comes alongside reports of a cardiac-device recall, increasing investor concerns about operational reliability, regulatory exposure and pressure on Boston Scientific’s growth outlook. The company has not yet quantified the financial impact of either issue. Boston Scientific hit with cardiac device recall

Boston Scientific Price Performance

BSX stock opened at $46.64 on Friday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The firm has a 50 day moving average price of $46.53 and a 200-day moving average price of $56.72. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $109.50. The firm has a market capitalization of $67.59 billion, a price-to-earnings ratio of 18.88, a PEG ratio of 1.05 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the business posted $0.75 EPS. The firm’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase plan on Monday, May 18th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig bought 5,000 shares of the company’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction dated Wednesday, August 5th. The shares were purchased at an average price of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have purchased 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on BSX. Raymond James Financial restated an “outperform” rating and issued a $57.00 target price on shares of Boston Scientific in a research note on Thursday, July 30th. TD Cowen reiterated a “buy” rating and issued a $56.00 price objective on shares of Boston Scientific in a report on Tuesday. Wells Fargo & Company decreased their price objective on Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a report on Thursday, July 30th. Mizuho lowered their price objective on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Finally, Royal Bank Of Canada dropped their target price on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, July 30th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.